ASH 2019: Blinatumomab Improves Outcomes in Relapsed B-ALL Better Than Intensive Chemotherapy in Young Patients
The drug represents a new standard of care in this setting, says study author
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.